[{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ Not Applicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"IL-15","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ Not Applicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ Not Applicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"HaNK","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"BM-Allo.MSC","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ Not Applicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ Not Applicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ NantKwest"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ NantKwest"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"BCG","moa":"IL-15","graph1":"Oncology","graph2":"Phase III","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"NantKwest \/ NantKwest","highestDevelopmentStatusID":"10","companyTruncated":"NantKwest \/ NantKwest"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NantKwest \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ NantKwest"},{"orgOrder":0,"company":"NantKwest","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ NantKwest","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ NantKwest"}]

Find Clinical Drug Pipeline Developments & Deals by NantKwest

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : hAd5 S+N is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous, sublingual, and oral.

                          Brand Name : hAd5 S+N

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 08, 2021

                          Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : ImmunityBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 15, 2021

                          Lead Product(s) : Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : CytRx Corporation

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The combination of NantKwest’s Natural Killer (NK) cell platform and ImmunityBio’s immunotherapy fusion protein, immunomodulator, and adenovirus platforms have already resulted in complete responses in late stage, difficult to treat metastatic cancer...

                          Brand Name : Anktiva

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 21, 2020

                          Lead Product(s) : N-803,BCG Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : ImmunityBio

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NA...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 21, 2020

                          Lead Product(s) : Aldoxorubicin HCl,N-803,PD-L1 t-haNK

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : ImmunityBio

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Developed by ImmunityBio and manufactured by NantKwest, this second generation hAd5-vector vaccine is unique in targeting both spike and nucleocapsid SARS-CoV-2 proteins. Low dose cohort reports no serious adverse events, high dose cohort safety analysis...

                          Brand Name : hAd5

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 10, 2020

                          Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : ImmunityBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : First patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the corona...

                          Brand Name : hAd5

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          October 21, 2020

                          Lead Product(s) : hAd5-S-Fusion+N-ETSD Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : ImmunityBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist AnktivaÔ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancr...

                          Brand Name : PD-L1 t-haNK

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          October 06, 2020

                          Lead Product(s) : PD-L1 t-haNK,N-803,Aldoxorubicin HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : ImmunityBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 18, 2020

                          Lead Product(s) : BM-Allo.MSC

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 14, 2020

                          Lead Product(s) : PD-L1 t-haNK,N-803,Aldoxorubicin HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Under this collaboration, NantKwest and ImmunityBio are combining their resources to design and develop therapeutics and vaccines for COVID-19.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 14, 2020

                          Lead Product(s) : HaNK

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : ImmunityBio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank